NeuroMetrix (NASDAQ:NURO) Vs. TELA, LQDA, TMDI, NMRD, TTOO, STIM, BWAY, PYPD, KRMD, and VERO
Should you be buying NeuroMetrix stock or one of its competitors? The main competitors of NeuroMetrix include TELA Bio (TELA), Liquidia (LQDA), Titan Medical (TMDI), Nemaura Medical (NMRD), T2 Biosystems (TTOO), Neuronetics (STIM), BrainsWay (BWAY), PolyPid (PYPD), Repro Med Systems (KRMD), and Venus Concept (VERO). These companies are all part of the "surgical & medical instruments" industry.
NeuroMetrix vs.
NeuroMetrix (NASDAQ:NURO) and Liquidia (NASDAQ:LQDA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.
NeuroMetrix received 127 more outperform votes than Liquidia when rated by MarketBeat users. Likewise, 71.72% of users gave NeuroMetrix an outperform vote while only 66.53% of users gave Liquidia an outperform vote.
Liquidia has a consensus target price of $5.00, suggesting a potential upside of 42.05%. Given Liquidia's higher possible upside, analysts clearly believe Liquidia is more favorable than NeuroMetrix.
6.0% of NeuroMetrix shares are owned by institutional investors. Comparatively, 20.5% of Liquidia shares are owned by institutional investors. 7.0% of NeuroMetrix shares are owned by insiders. Comparatively, 29.5% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
NeuroMetrix has higher revenue and earnings than Liquidia.
Liquidia has a net margin of 0.00% compared to NeuroMetrix's net margin of -14.30%. NeuroMetrix's return on equity of -19.02% beat Liquidia's return on equity.
In the previous week, NeuroMetrix had 1 more articles in the media than Liquidia. MarketBeat recorded 5 mentions for NeuroMetrix and 4 mentions for Liquidia. NeuroMetrix's average media sentiment score of 0.61 beat Liquidia's score of 0.42 indicating that NeuroMetrix is being referred to more favorably in the media.
NeuroMetrix has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500.
Summary
NeuroMetrix beats Liquidia on 9 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NURO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip ChartNeuroMetrix (NASDAQ:NURO) vs. Its Competitors
NeuroMetrix Competitors List
